In one of the largest regenerative medicine deals of 2026 to date, UCB has announced plans to acquire Neurona Therapeutics in a transaction valued at an astounding price tag: up to $1.15 billion. The deal includes $650 million upfront, with an additional $500 million tied to future milestones, underscoring the scale of UCB’s commitment to next-generation therapeutic modalities. [Read more…]
The Top Life Science & Biotech Conferences to Attend in the U.S. in 2026
The 2026 biotech conferences calendar is one of the densest years biopharma and the broader life sciences industry have seen.
FDA approval velocity remains high. Inflation Reduction Act implementation is entering a more consequential phase. Generative AI is moving from R&D experimentation into operational deployment. And biotech investment trends point to a re-opening capital environment after a multi-year reset.
All of that translates into a packed year of events competing for commercial, R&D, investor, and executive attention. [Read more…]
MSCs: A Multi-Version Medicinal Technology System, Part I
The Most Interesting Things Take Time
The world’s first approved product from monoclonal antibody technology was Muromonab-CD3 (Orthoclone OKT3), launched in 1986. It’s a prime example of “mAb version 1.0,” unleashed before a wave of newer, more manufacturable and better engineered products would begin to enter the market in the late-90s. Later molecular and process iterations based on “mAb 1.0” would take several decades to finally ramify into diverse platforms such as CAR-T, Bi-specific T-cell engagers (BiTEs), diagnostics, and biosensors. As a cellular technology platform, mesenchymal stem/stromal cells (MSCs) are proceeding with a story of convergent evolution. [Read more…]
A Multi-Version Medicinal Technology System, Part II
A New Generation of MSC Applications
With scientific results dismally challenging to replicate properly across disciplines, scientists, technologists, or investors with intact survival instincts cannot be naïve. No matter how gruff it sounds, a healthy respect for due diligence and fiduciary responsibility demands that good people ask, “Where’s the beef!?” at any time. In Part I of this article, we first heard about “MSC 2.0,” 17 which is the second generation of mesenchymal stem/stromal cell (MSC) cellular technology. Like T cells, MSCs are a raw primary cellular source that irrigates multiple branches of downstream clinical applications that intermingle with other technologies. Although one potentially promising use of “v2.0” involves cell-cultured and/or cruelty-free meat (aka “clean meat”), 76 we aim to inform you here that MSC 2.0 now supports other—more near-term—ventures of direct benefit to human health. [Read more…]
Green Elephant Biotech Introduces Archimedes® One, the First Dynamic Adherent Bioreactor for Cell Therapy Manufacturing
Giessen, Germany – 17.03.2026 – Green Elephant Biotech announces the market introduction of Archimedes® One, the first system in a new category called the Dynamic Adherent Bioreactor. The company is introducing the platform to the market ahead of its planned commercial launch later this year.
Archimedes® One was developed to address a central challenge in cell therapy manufacturing: how to scale adherent cell processes without compromising biology or introducing unnecessary complexity. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 62
- Next Page »




